Indexing
All Issues
Submission
Author Guidelines
Reviewers
Editorial Members
Publication Fee
Vol.1 , No. 1, Publication Date: Apr. 1, 2015, Page: 1-9
 as Crisis Management Tools for Important Health Problems&description=Important current diseases manifest to cover metabolic diseases, respiratory allergies, gastrointestinal (GI) diseases, genital infections, certain neurological disorders, autoimmune disorders, and musculoskeletal pain and fatigue. Patients with these diseases have been known to respond favorably to a treatment method of increasing dosages of composite selective probiotics, (probiotics and paraprobiotics) and probiotical cell fragments (PCFs) supplements. PCFs such as of lactobacilli and bifidobacteria benefit the GI system and have shown substantial local immune enhancing benefits. These treatment methods have demonstrated positive results in 85.5% of cases of chronic tonsillitis and 90% in maxilloethmoidal sinusitis. Consistent amounts of probiotics have been quantified for therapeutic microbial activities on a broad spectrum of pathogenic Candida species in otolaryngology and genital organs, respectively. The combined effects of this article enable selective probiotics and their derivatives as valuable tools for clinical employment in the prevention and adjunctive treatment of significant current diseases.&picture=http://www.aascit.org/aascit/decorators/img/journal/979.jpg)
| [1] | Nditange Shigwedha, School of Food Science and Engineering, Harbin Institute of Technology, Harbin, China; Pure Research Products, LLC, Boulder, Colorado, USA; Department of Food Science and Technology, University of Namibia, Windhoek, Namibia. |
| [2] | Liubov Sichel, Pure Research Products, LLC, Boulder, Colorado, USA. |
| [3] | Li Jia, Wyeth Nutrition, Suzhou, China. |
| [4] | Anika Niambi Al-Shura, Niambi Wellness, LLC, Tampa, Florida, USA. |
| [5] | Lanwei Zhang, School of Food Science and Engineering, Harbin Institute of Technology, Harbin, China. |
Important current diseases manifest to cover metabolic diseases, respiratory allergies, gastrointestinal (GI) diseases, genital infections, certain neurological disorders, autoimmune disorders, and musculoskeletal pain and fatigue. Patients with these diseases have been known to respond favorably to a treatment method of increasing dosages of composite selective probiotics, (probiotics and paraprobiotics) and probiotical cell fragments (PCFs) supplements. PCFs such as of lactobacilli and bifidobacteria benefit the GI system and have shown substantial local immune enhancing benefits. These treatment methods have demonstrated positive results in 85.5% of cases of chronic tonsillitis and 90% in maxilloethmoidal sinusitis. Consistent amounts of probiotics have been quantified for therapeutic microbial activities on a broad spectrum of pathogenic Candida species in otolaryngology and genital organs, respectively. The combined effects of this article enable selective probiotics and their derivatives as valuable tools for clinical employment in the prevention and adjunctive treatment of significant current diseases.
Keywords
Important Diseases, Metabolic Diseases, Respiratory Allergies, Genital Infections, Gastrointestinal (GI) Disease, Neurological Disorders, Orthopedic Diseases, Composite Selective Probiotics, Probiotical Cell Fragments (PCFs)
Reference
| [01] | K. Sivieri, R. Bedani, D. C. U. Cavallini, and E. A. Rossi, “Probiotics and Intestinal Microbiota: Implications in Colon Cancer Prevention,” In: Lactic Acid Bacteria—R & D for Food, Health and Livestock Purposes, M. Kongo, editor, InTech, Croatia, pp. 217–262, 2013. |
| [02] | G. Danaei, M. M. Finucane, Y. Lu, G. M. Singh, M. J. Cowan, C. J. Paciorek, J. K. Lin, F. Farzadfar, Y. H. Khang, G. A. Stevens, M. Rao, M. K. Ali, L. M. Riley, C. A. Robinson, and M. Ezzati,“National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants,” The Lancet, vol. 378, no. 9785, pp. 31–40, 2011. |
| [03] | M. Hirst, “Diabetes in 2013. The new figures,” Diabetes Research and Clinical Practice, vol. 102, no. 3, pp. 265, 2013. |
| [04] | W. Yang, J. Lu, J. Weng, W. Jia, L. Ji, J. Xiao, Z. Shan, J. Liu, H. Tian, Q. Ji, D. Zhu, J. Ge, L. Lin, L. Chen, X. Guo, Z. Zhao, Q. Li, Z. Zhou, G. Shan, and J. He, “Prevalence of diabetes among men and women in China”, The New England Journal of Medicine, vol. 362, no. 12, pp. 1090–1101, 2010. |
| [05] | A. Pihlanto, “Lactic Fermentation and Bioactive Peptides” In: Lactic Acid Bacteria—R & D for Food, Health and Livestock Purposes, M. Kongo, editor, InTech, Croatia, pp. 309–332, 2013. |
| [06] | U. Risérus, W. C. Willett, and F. B. Hu, “Dietary fats and prevention of type 2 diabetes,” Progress in Lipid Research, vol. 48, no. 1, pp. 44–51, 2009. |
| [07] | A. Rubio-Tapia and J. A. Murray, “Gluten-Sensitive Enteropathy,” In: Food allergy: adverse reactions to foods and food additives, D. D. Metcalfe, H. A. Sampson, R. A. Simon, and G. Lack, editors, Wiley-Blackwell Publishing Ltd., Oxford, UK, pp. 217–229, 2013. |
| [08] | R. Burcelin, M. Serino, C. Chabo, V. Blasco-Baque, and J. Amar, “Gut microbiota and diabetes: from pathogenesis to therapeutic perspective,” Acta Diabetologica, vol. 48, no. 4, pp. 257–273, 2011. |
| [09] | Ö. C. O. Umu, M. Oostindjer, P. B. Pope, B. Svihus, B. Egelandsdal, I. F. Nes, and D. B. Diep, “Potential applications of gut microbiota to control human physiology”. Antonie van Leeuwenhoek, vol. 104, no. 5, pp. 609–618, 2013. |
| [10] | R. D. West, E. Roberts, L. S. Sichel, and J Sichel, “Improvements in gastrointestinal symptoms among children with autism spectrum disorder receiving the Delpro® probiotic and immunomodulator formulation,” Journal of Probiotics and Health, vol. 1, no. 1, e1000102, 2013. |
| [11] | J. F. Ludvigsson, S. M. Montgomery, A. Ekbom, L. Brandt, and F. Granath, “Small intestinal histopathology and mortality risk in celiac disease,” The Journal of the American Medical Association, vol. 302, no. 11, pp. 1171–1178, 2009. |
| [12] | N. Shigwedha, L. Sichel, L. Jia, and L. Zhang, “Probiotical Cell Fragments (PCFs) as “novel nutraceutical ingredients”,” Journal of Biosciences and Medicines, vol. 2, no. 3, pp. 43–55, 2014. |
| [13] | N. Shigwedha, L. Zhang, L. Sichel, L. Jia, P. Gong, W. Liu, S. Wang, S. Zhang, X. Han, and W. Gao, “More than a few LAB alleviate common allergies: Impact of paraprobiotics in comparison to probiotical live cells,” Journal of Biosciences and Medicines, vol. 2, no. 3, pp. 56–64, 2014. |
| [14] | R. E. Ley, M. Hamady, C. Lozupone, P. Turnbaugh, R. R. Ramey, J. S. Bircher, M. L. Schlegel, T. A. Tucker, M. D. Schrenzel, R. Knight, and J. I. Gordon, “Evolution of mammals and their gut microbes,” Science, vol. 320, no. 5883, pp. 1647–1651, 2008. |
| [15] | N. Larsen, F. K. Vogensen, F. W. J. Van den Berg, D. S. Nielsen, A. S. Andreasen, B. K. Pedersen, W. A. Al-Soud, S. J. Sørensen, L. H. Hansen, and M. Jakobsen, “Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults,” PloS One, vol. 5, no. 2, e9085, 2010. |
| [16] | M. Murri, I. Leiva, J. M. Gomez-Zumaquero, F. J. Tinahones, F. Cardona, F. Soriguer, and M. I. Queipo-Ortuño, “Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study,”BioMed Central Medicine, vol. 11, no. 1, pp. e46,2013. |
| [17] | P. J. Turnbaugh, M. Hamady, T. Yatsunenko, B. L. Cantarel, A. Duncan, R. E. Ley, M. L. Sogin, W. J. Jones, B. A. Roe, J. P. Affourtit, M. Egholm, B. Henrissat, A. C. Heath, R. Knight, and J. I. Gordon, “A core gut microbiome in obese and lean twins,” Nature, vol. 457, no. 7228, pp. 480–484, 2009. |
| [18] | N. A. Berger, “Obesity and cancer pathogenesis,” Annals of the New York Academy of Sciences, vol. 1311, pp. 57–76, 2014. |
| [19] | A. S. Neish, “Microbes in gastrointestinal health and disease,” Gastroenterology, vol. 136, no. 1, pp. 65–80, 2009. |
| [20] | R. E. Ley, D. A. Peterson, and J. I. Gordon, “Ecological and evolutionary forces shaping microbial diversity in the human intestine,” Cell, vol. 124, no. 4, pp. 837–848, 2006. |
| [21] | F. Bäckhed, R. E. Ley, J. L. Sonnenburg, D. A. Peterson, and J. I. Gordon, “Host-bacterial mutualism in the human intestine,” Science, vol. 307, no. 1 5717, pp. 1915–1920, 2005. |
| [22] | G. Musso, R. Gambino, and M. Cassader, “Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded?,” Diabetes Care, vol. 33, no. 10, pp. 2277–2284, 2010. |
| [23] | K. E. Wellen and G. S. Hotamisligil, “Inflammation, stress, and diabetes,” The Journal of Clinical Investigation, vol. 115, no. 5, pp. 1111–1119, 2005. |
| [24] | S. Ding, M. M. Chi, B. P. Scull, R. Rigby, N. M. J. Schwerbrock, S. Magness, C. Jobin, and P. K. Lund, “High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse,” PloS One, vol. 5, no. 8, e12191, 2010. |
| [25] | P. D. Cani, J. Amar, M. A. Iglesias, M. Poggi, C. Knauf, D. Bastelica, A. M. Neyrinck, F. Fava, K. M. Tuohy, C. Chabo, A. Waget, E. Delmée, B. Cousin, T. Sulpice, B. Chamontin, J. Ferrières, J. F. Tanti, G. R. Gibson, L. Casteilla, N. M. Delzenne, M. C. Alessi, and R. Burcelin, “Metabolic endotoxemia initiates obesity and insulin resistance,”Diabetes, vol. 56, no. 7, pp. 1761–1772, 2007. |
| [26] | P. D. Cani, R. Bibiloni, C. Knauf, A. Waget, A. M. Neyrinck, N. M. Delzenne, and R. Burcelin, “Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice,” Diabetes, vol. 57, no. 6, pp. 1470–1481, 2008. |
| [27] | S. Lebeer, J. Vanderleyden, and C. J. de Keersmaecker, “Host Interactions of probiotic bacterial surface molecules: Comparison with commensals and pathogens,” Nature Reviews Microbiology, vol. 8, pp. 171–184, 2010. |
| [28] | H. Liang, S. E. Hussey, A. Sanchez-Avila, P. Tantiwong, and N. Musi, “Effect of lipopolysaccharide on inflammation and insulin action in human muscle,” PloS One, vol. 8, no. 5, e63983, 2013. |
| [29] | A. M. Caricilli, P. K. Picardi, L. L. de Abreu, M. Ueno, P. O. Prada, E. R. Ropelle, S. M. Hirabara, A. Castoldi, P. Vieira, N. O. S. Camara, R. Curi, J. B. Carvalheira, and M. J. A. Saad,“Gut microbiota is a key modulator of insulin resistance in TLR 2 knockout mice” PLoS Biology, vol. 9, no. 12, e1001212, 2011. |
| [30] | T. Kawai, and S. Akira, “Toll-like receptors and their crosstalk with other innate receptors in infection and immunity,” Immunity, vol. 34, no. 5, pp. 637–650, 2011. |
| [31] | M. Miettinen, V. Veckman, S. Latvala, T. Sareneva, S Matikainen, and I. Julkunen, “Live Lactobacillus rhamnosus and Streptococcus pyogenes differentially regulate toll-like receptor (TLR) gene expression in human primary macrophages,” Journal of Leukocyte Biology, vol. 84, no. 4, pp. 1092–1100, 2008. |
| [32] | S. de Kort, D. Keszthelyi, and A. A.Masclee, “Leaky gut and diabetes mellitus: what is the link?,” Obesity Reviews, vol. 12, no. 6, pp. 449–458, 2011. |
| [33] | P. D. Cani, S. Possemiers, T. van de Wiele, Y. Guiot, A. Everard, O. Rottier, L. Geurts, D. Naslain, A. Neyrinck, D. M. Lambert, G. G. Muccioli, and N. M. Delzenne, “Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability,” Gut, vol. 58, no. 8, pp. 1091–1103, 2009. |
| [34] | P. E. Dube and P. L. Brubaker, “Nutrient, neural and endocrine control of glucagon-like peptide secretion,”Hormone and Metabolic Research, vol. 36, no. 11/12, pp. 755–760, 2004. |
| [35] | P. E. Dube, K. J. Rowland, and P. L. Brubaker, “Glucagon-like peptide-2 activates beta-catenin signaling in the mouse intestinal crypt: role of insulin-like growth factor-I,” Endocrinology, vol. 149, no. 1, pp. 291–301, 2008. |
| [36] | P. E. Dube, C. L. Forse, J. Bahrami, and P. L. Brubaker, “The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice,” Gastroenterology, vol. 131, no. 2, pp. 589–605, 2006. |
| [37] | L. Sichel, D. Zabolotna, and D. Zabolotny, “Perspectives of probiotic therapy in sinus infection”, Available at http://www.lyoferm.com/research, Accessed March 21, 2015. |
| [38] | S. Alvarez, J. Villena, M. Tohno, S. Salva, and H. Kitazawa, “Modulation of innate immunity by lactic acid bacteria: impact on host response to infections,” Current Resources in Immunology, vol. 3, pp. 87–126, 2009. |
| [39] | S. Racedo, J. Villena, M. Medina, G. Agüero, V. Rodríguez, and S. Alvarez, “Lactobacillus casei administration reduces lung injuries in a Streptococcus pneumoniae infection in mice,” Microbes and Infections,vol.8, no. 9-10, pp. 2359–2366, 2006. |
| [40] | S. Racedo, J. Villena, S. Salva, and S. Alvarez. “Influence of yogurt consumption on the respiratory immune response,”Food and Agricultural Immunology, vol. 20, no.3, pp. 231–244, 2009. |
| [41] | J. Villena, M. Medina, E. Vintiñi, and S. Alvarez, “Stimulation of respiratory immunity by oral administration of Lactococcus lactis,”Canadian Journal of Microbiology, vol. 54, no. 8, pp. 630–638, 2008. |
| [42] | S. Salva, J. Villena, and S. Alvarez, “Differential immunomodulatory activity of Lactobacillus rhamnosus strains isolated from goat milk: impact on intestinal and respiratory infections,”International Journal of Food Microbiology, vol. 141, no. 1-2, pp. 82–89, 2010. |
| [43] | A. Tanaka, M. Seki, S. Yamahira, H. Noguchi, K. Kosai, M. Toba, Y. Morinaga, T. Miyazaki, K. Izumikawa, H. Kakeya, Y. Yamamoto, K. Yanagihara, T. Tashiro, N. Kohda, and S. Kohno, “Lactobacillus pentosus strain b240 suppresses pneumonia induced by Streptococcus pneumoniae in mice,” Letters in Applied Microbiology, vol. 53, no. 1, pp. 35–43, 2011. |
| [44] | O. G. Volska, L. M. Shynkarenko, I. S. Zarytska, and D. D. Zabolotna, “Study of the possibility of using lactobacilli in prevention and treatment of candidosis in otolaryngological organs,” Odessa Medical Journal, vol. 4, no. 96, pp. 32–36, 2006. (Ukrainian) |
| [45] | P. G. Larsson, E. Brandsborg, U. Forsum, S. Pendharkar, K. K. Andersen, S. Nasic, L. Hammarström, and H. Marcotte, “Extended antimicrobial treatment of bacterial vaginosis combined with human lactobacilli to find the best treatment and minimize the risk of relapses,” BioMed Central Infectious Diseases, vol. 11, no. 1, pp. 223, 2011. |
| [46] | W. Ya, C. Reifer, and L. E. Miller, “Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: a double-blind, randomized, placebo-controlled study,” American Journal of Obstetrics and Gynecology, vol. 203, no. 2, pp. 120-e1, 2010. |
| [47] | A. Homayouni, P. Bastani, S. Ziyadi, S. Mohammad-Alizadeh-Charandabi, M. Ghalibaf, A. M. Mortazavian, and E. V. Mehrabany, “Effects of probiotics on the recurrence of bacterial vaginosis: A review,” Journal of Lower Genital Tract Disease, vol. 18, no. 1, pp. 79–86, 2014. |
| [48] | P. Hay, “Bacterial vaginosis,” Medicine, vol. 42, no. 7, pp. 359–363, 2014. |
| [49] | C. M. Galdeano, A. C. Dogi, and G. Perdigón, “Difference in the signals induced by commensal or probiotic bacteria to the gut epithelial and immune cells,” In: Probiotics: Immunobiotics and Immunogenics, H. Kitazawa, J. Villena, and S. Alvarez, editors, CRC Press, Boca Raton, pp. 36–53, 2013. |
| [50] | H. N. Youn, D. H. Lee, Y. N. Lee, J. K. Park, S. S. Yuk, S. Y. Yang, H. J. Lee, S. H. Woo, H. M. Kim, J. B. Lee, S. Y. Park, I. S. Choi, and C. S. Song, “Intranasal administration of live Lactobacillus species facilitates protection against influenza virus infection in mice,” Antiviral Research, vol. 93, no. 1, pp. 138–143, 2012. |
| [51] | J. Villena, S. Salva, N. Barbieri, and S. Alvarez, “Immunobiotics for the prevention of bacterial and viral respiratory infections,” In: Probiotics: Immunobiotics and Immunogenics, H. Kitazawa, J. Villena, and S. Alvarez, editors, CRC Press, Boca Raton, pp. 128–168, 2013. |
| [52] | F. J. Culley, “Natural killer cells in infection and inflammation of the lung,” Immunology, vol. 128, no. 2, pp. 151–163, 2009. |
| [53] | T. Strowig, F. Brilot, and C. Münz, “Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity,” The Journal of Immunology, vol. 180, no. 12, pp. 7785–7791, 2008. |
| [54] | M. H. Zelaya, and M. G. Agüero, “Immunobiotics and Inflammation-Coagulation,” In: Probiotics: Immunobiotics and Immunogenics, H. Kitazawa, J. Villena, and S. Alvarez, editors, CRC Press, Boca Raton, pp. 248–279, 2013. |
| [55] | J. L. Strominger, “Bacterial cell walls, innate immunity and immunoadjuvants,”Nature Immunology, vol. 8, pp. 1269–1271, 2007. |
| [56] | Del-Immune V®. http://www.delimmune.com/research, Accessed March 24, 2015. |
